Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
In 2 phase 3 trials examining the concept of triweekly dosing with the long-acting insulin degludec (Tresiba, Novo Nordisk) in patients with type 2 diabetes, the recipients had inferior glucose control and an increased risk for hypoglycemia in the first 24 hours with this less frequent dosing regimen, compared with the comparator, daily insulin glargine (Lantus, Sanofi).
In a paper reporting these 2 trials, the authors conclude that the overall risk-to-benefit ratio does not support a 3-times-a-week dosing of insulin degludec, and this basal insulin should be used only in a once-daily dosing regimen.
"I was very anxious that these 2 phase 3 studies get published, because they don't support the phase 2 study [that suggested a benefit of triweekly dosing]," lead author Bernard Zinman, MD, from the Samuel Lunenfeld Research Center and the University of Toronto, Ontario, told Medscape Medical News. "The bottom line is this insulin is meant to be used daily."
http://www.medscape.com/viewarticle/807671
Yup, sounds like a bad idea to me given that a lot of people even need to split their once-a-day insulins! 🙄
In a paper reporting these 2 trials, the authors conclude that the overall risk-to-benefit ratio does not support a 3-times-a-week dosing of insulin degludec, and this basal insulin should be used only in a once-daily dosing regimen.
"I was very anxious that these 2 phase 3 studies get published, because they don't support the phase 2 study [that suggested a benefit of triweekly dosing]," lead author Bernard Zinman, MD, from the Samuel Lunenfeld Research Center and the University of Toronto, Ontario, told Medscape Medical News. "The bottom line is this insulin is meant to be used daily."
http://www.medscape.com/viewarticle/807671
Yup, sounds like a bad idea to me given that a lot of people even need to split their once-a-day insulins! 🙄